Exploring the versatility of Drosophila melanogaster as a model organism in biomedical research: a comprehensive review

Fly (Austin). 2025 Dec;19(1):2420453. doi: 10.1080/19336934.2024.2420453. Epub 2024 Dec 25.

Abstract

Drosophila melanogaster is a highly versatile model organism that has profoundly advanced our understanding of human diseases. With more than 60% of its genes having human homologs, Drosophila provides an invaluable system for modelling a wide range of pathologies, including neurodegenerative disorders, cancer, metabolic diseases, as well as cardiac and muscular conditions. This review highlights key developments in utilizing Drosophila for disease modelling, emphasizing the genetic tools that have transformed research in this field. Technologies such as the GAL4/UAS system, RNA interference (RNAi) and CRISPR-Cas9 have enabled precise genetic manipulation, with CRISPR-Cas9 allowing for the introduction of human disease mutations into orthologous Drosophila genes. These approaches have yielded critical insights into disease mechanisms, identified novel therapeutic targets and facilitated both drug screening and toxicological studies. Articles were selected based on their relevance, impact and contribution to the field, with a particular focus on studies offering innovative perspectives on disease mechanisms or therapeutic strategies. Our findings emphasize the central role of Drosophila in studying complex human diseases, underscoring its genetic similarities to humans and its effectiveness in modelling conditions such as Alzheimer's disease, Parkinson's disease and cancer. This review reaffirms Drosophila's critical role as a model organism, highlighting its potential to drive future research and therapeutic advancements.

Keywords: Drosophila melanogaster; cancer; cardiac diseases; disease modelling; genetic tools; metabolic diseases; muscular diseases; neurodegeneration.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomedical Research
  • CRISPR-Cas Systems
  • Disease Models, Animal*
  • Drosophila melanogaster* / genetics
  • Humans

Grants and funding

The author gratefully acknowledges the financial support provided to the first author by the International Society for Neurochemistry (ISN) through the CAEN Category 1A grant. This funding was instrumental in facilitating the preparation of this review.